The emerging pillars of chronic kidney disease: no longer a bystander in metabolic medicine

Wonnacott, Alexa ORCID: https://orcid.org/0000-0002-0968-4248 2023. The emerging pillars of chronic kidney disease: no longer a bystander in metabolic medicine. Clinical Medicine 23 (3) , pp. 254-258. 10.7861/clinmed.2023-RM1

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (177kB) | Preview

Abstract

Chronic kidney disease (CKD) represents an enormous healthcare burden, the management of which has been stagnant for the last couple of decades, with blockade of the renin–angiotensin–aldosterone system (RAAS) the most potent tool available to retard kidney disease progression. In the new cardiometabolic era, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as forerunners in addressing combined cardiorenal risk. This review summarises the evidence for SGLT2i use in diabetic and non-diabetic CKD and examines the risk:benefit profile in this population. Novel non-steroidal mineralocorticoid receptor antagonists are also considered as an emerging pillar of CKD management, and their role in optimising the cardiorenal health of patients with diabetic kidney disease is discussed.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Publisher:	Royal College of Physicians
ISSN:	1470-2118
Date of First Compliant Deposit:	15 March 2024
Last Modified:	15 Mar 2024 12:14
URI:	https://orca.cardiff.ac.uk/id/eprint/166952

Actions (repository staff only)

Edit Item